Pages that link to "Q33976264"

The following pages link to A novel interaction between HER2/neu and cyclin E in breast cancer (Q33976264):

Displaying 35 items.

• Novel Molecular Markers for Breast Cancer (Q26753160) (← links)
• The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity (Q34073138) (← links)
• LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients (Q34220979) (← links)
• Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis (Q34452426) (← links)
• Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women (Q34489947) (← links)
• Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 breast cancer patients (Q34621219) (← links)
• Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis (Q35077315) (← links)
• Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance (Q35624814) (← links)
• Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer (Q35684440) (← links)
• Target points in trastuzumab resistance (Q35821286) (← links)
• Inference of tumor phylogenies from genomic assays on heterogeneous samples (Q35986538) (← links)
• Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications (Q36088788) (← links)
• Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response (Q36096051) (← links)
• Reinforcing targeted therapeutics with phenotypic stability factors (Q36187514) (← links)
• Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87 (Q36642333) (← links)
• Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients (Q36729467) (← links)
• Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006 (Q36810717) (← links)
• CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment. (Q36881905) (← links)
• Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer (Q37057171) (← links)
• HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth (Q37269081) (← links)
• Novel multisample scheme for inferring phylogenetic markers from whole genome tumor profiles (Q37315891) (← links)
• Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells (Q37565022) (← links)
• HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2 breast cancer (Q37699133) (← links)
• The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications (Q37948079) (← links)
• Emerging targeted agents in metastatic breast cancer (Q38086421) (← links)
• Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond (Q38675849) (← links)
• Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer (Q38924681) (← links)
• Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells. (Q39359785) (← links)
• Growth hormone receptor (GHR) RNAi decreases proliferation and enhances apoptosis in CMT-U27 canine mammary carcinoma cell line (Q39413877) (← links)
• Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer (Q40951473) (← links)
• Cell Cycle Regulation in Treatment of Breast Cancer. (Q49544319) (← links)
• Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. (Q49558301) (← links)
• Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. (Q52955581) (← links)
• Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies (Q60017682) (← links)
• Targeting tumor cells with antibodies enhances anti-tumor immunity (Q90382339) (← links)